Amneal Pharmaceuticals - Class A (AMRX) closed at $19.45 on November 5, 2026, down 2.5% from the previous close, on volume of 2,011,026 shares (30-day average 4,025,090).
Data as of November 5, 2026.
5-Nov-2026
Leerink Partners Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)
TipRanks (Thu, 5-Nov 9:31 AM ET)
Amneal Pharmaceuticals Reports Strong Third-Quarter 2026 Financial Results
TipRanks (Tue, 3-Nov 8:53 AM ET)
Amneal Pharmaceuticals (AMRX) Receives a Buy from Oppenheimer
TipRanks (Tue, 3-Nov 8:36 AM ET)
Amneal raises 2026 forecast but lowers operating cash flow outlook
Seeking Alpha News (Tue, 3-Nov 6:12 AM ET)
Amneal Reports Third Quarter 2026 Financial Results
Globe Newswire (Tue, 3-Nov 6:00 AM ET)
Here are the major earnings before the open Tuesday
Seeking Alpha News (Mon, 2-Nov 6:00 PM ET)
Amneal Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha News (Mon, 2-Nov 10:14 AM ET)
Amneal to Report Third Quarter 2026 Results on November 3, 2026
Globe Newswire (Thu, 8-Oct 8:00 AM ET)
Amneal Launches FDA-Approved Lanreotide, Targeting a $983 Million Reference Market
Market Chameleon (Mon, 21-Sep 7:15 AM ET)
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Globe Newswire (Fri, 18-Sep 4:01 PM ET)
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Amneal Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol AMRX.
As of November 5, 2026, AMRX stock price declined to $19.45 with 2,011,026 million shares trading.
AMRX has a beta of 0.56, meaning it tends to be less sensitive to market movements. AMRX has a correlation of 0.04 to the broad based SPY ETF.
AMRX has a market cap of $6.77 billion. This is considered a Mid Cap stock.
Last quarter Amneal Pharmaceuticals - Class A reported $863 million in Revenue and $.26 earnings per share. This beat revenue expectation by $45 million and exceeded earnings estimates by $.02.
In the last 3 years, AMRX traded as high as $21.68 and as low as $3.96.
The top ETF exchange traded funds that AMRX belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
AMRX has outperformed the market in the last year with a price return of +71.4% while the SPY ETF gained +9.7%. AMRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.2% and -3.7%, respectively, while the SPY returned -4.7% and -5.2%, respectively.
AMRX support price is $19.55 and resistance is $20.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMRX shares will trade within this expected range on the day.